1. Home
  2. TELA vs SCLX Comparison

TELA vs SCLX Comparison

Compare TELA & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TELA
  • SCLX
  • Stock Information
  • Founded
  • TELA 2012
  • SCLX 2011
  • Country
  • TELA United States
  • SCLX United States
  • Employees
  • TELA N/A
  • SCLX N/A
  • Industry
  • TELA Medical/Dental Instruments
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TELA Health Care
  • SCLX Health Care
  • Exchange
  • TELA Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • TELA 36.4M
  • SCLX 33.9M
  • IPO Year
  • TELA 2019
  • SCLX N/A
  • Fundamental
  • Price
  • TELA $1.68
  • SCLX $4.73
  • Analyst Decision
  • TELA Strong Buy
  • SCLX Strong Buy
  • Analyst Count
  • TELA 4
  • SCLX 3
  • Target Price
  • TELA $6.00
  • SCLX $367.50
  • AVG Volume (30 Days)
  • TELA 181.8K
  • SCLX 133.7K
  • Earning Date
  • TELA 08-11-2025
  • SCLX 08-12-2025
  • Dividend Yield
  • TELA N/A
  • SCLX N/A
  • EPS Growth
  • TELA N/A
  • SCLX N/A
  • EPS
  • TELA N/A
  • SCLX N/A
  • Revenue
  • TELA $71,217,000.00
  • SCLX $50,710,000.00
  • Revenue This Year
  • TELA $26.67
  • SCLX $107.00
  • Revenue Next Year
  • TELA $22.63
  • SCLX $82.52
  • P/E Ratio
  • TELA N/A
  • SCLX N/A
  • Revenue Growth
  • TELA 12.78
  • SCLX 7.79
  • 52 Week Low
  • TELA $0.86
  • SCLX $3.60
  • 52 Week High
  • TELA $5.56
  • SCLX $78.05
  • Technical
  • Relative Strength Index (RSI)
  • TELA 55.94
  • SCLX 42.52
  • Support Level
  • TELA $1.48
  • SCLX $4.56
  • Resistance Level
  • TELA $1.80
  • SCLX $4.90
  • Average True Range (ATR)
  • TELA 0.21
  • SCLX 0.58
  • MACD
  • TELA -0.03
  • SCLX -0.10
  • Stochastic Oscillator
  • TELA 49.33
  • SCLX 4.73

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: